Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Vigil Neuroscience's Enterprise Value is $-16.33 Mil.
Vigil Neuroscience's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 was $-88.43 Mil. Therefore, Vigil Neuroscience's EV-to-EBIT ratio for today is 0.18.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Vigil Neuroscience's Enterprise Value is $-16.33 Mil.
Vigil Neuroscience's EBITDA for the trailing twelve months (TTM) ended in Sep. 2024 was $-87.97 Mil. Therefore, Vigil Neuroscience's EV-to-EBITDA ratio for today is 0.19.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Vigil Neuroscience's Enterprise Value is $-16.33 Mil.
Vigil Neuroscience's Revenue for the trailing twelve months (TTM) ended in Sep. 2024 was $0.00 Mil. Therefore, Vigil Neuroscience's EV-to-Revenue ratio for today is .
Vigil Neuroscience Enterprise Value Historical Data
The historical data trend for Vigil Neuroscience's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Vigil Neuroscience's Enterprise Value
For the Biotechnology subindustry, Vigil Neuroscience's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vigil Neuroscience's Enterprise Value Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vigil Neuroscience's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Vigil Neuroscience's Enterprise Value falls into.
Vigil Neuroscience Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Vigil Neuroscience's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vigil Neuroscience (NAS:VIGL) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Vigil Neuroscience's current Enterprise Value is $-16.33 Mil.
Vigil Neuroscience's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-88.43 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Vigil Neuroscience's current Enterprise Value is $-16.33 Mil.
Vigil Neuroscience's EBITDA for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-87.97 Mil.
Vigil Neuroscience's current Enterprise Value is $-16.33 Mil.
Vigil Neuroscience's Revenue for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vigil Neuroscience Enterprise Value Related Terms
Thank you for viewing the detailed overview of Vigil Neuroscience's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
VIGL has been successfully added to your 